However, the subgroups of patients with CRC stratified by sex and subsequent tumor location had distinctive molecular patterns of PD-L1 expression, MMR/MSI status, and EGFR expression, which could have a potential predictive role in patient screening for combination therapies. This evidence concerns the gene EGFR and colorectal carcinoma.